Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are a well-established therapy for the treatment of EGFR-activating mutation-positive non-small-cell lung cancer (NSCLC) [1]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.